Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896144 | 0.88 | MAPK14 (0.65) | MAPK14MAP4K4 | |
| SCHEMBL3890143 | 0.82 | MAPK14 (0.58) | MAPK14TGFBR1ROCK1MAP4K4RORB | |
| SCHEMBL3890883 | 0.80 | MAPK14 (0.77) | MAPK14MAP4K4 | |
| SCHEMBL3901645 | 0.78 | MAPK14 (0.59) | MAPK14MAP4K4 | |
| SCHEMBL3899165 | 0.78 | MAPK14 (0.64) | MAPK14TGFBR1ROCK1 | |
| SCHEMBL3901366 | 0.77 | MAPK14 (0.60) | MAPK14TGFBR1ROCK1MAP4K4CDC7 | |
| SCHEMBL3887612 | 0.75 | MAPK14 (0.47) | MAPK14TGFBR1ROCK1MAP4K4CDC7 | |
| SCHEMBL3890930 | 0.75 | MAPK14 (0.58) | MAPK14TGFBR1ROCK1 | |
| SCHEMBL3889480 | 0.74 | MAPK14 (0.56) | MAPK14TGFBR1MAP4K4RORBCDC7 | |
| SCHEMBL3888103 | 0.70 | MAPK14 (0.76) | MAPK14MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1268474-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | MAPK1, MAP4K2, MAPK4 | MAPK14 31/4885TGFBR1 818/4885ROCK1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.